To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics Lic ...

Ci Distribution has added Unified Endpoint Management (UEM) specialist 42Gears to its UK portfolio, expanding the distributor’s reach in enterprise mobility and device security. The agreement gives Ci ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

Xiaomi Corporation has released its eighth annual Environmental, Social, and Governance (ESG) Report for 2025, which ...

The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...

Examine how large-scale screening of AI-designed binders informs CAR T-cell engineering and functional validation.

Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...

US FDA grants priority review to sBLA for Padcev+Keytruda as perioperative treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility: Tokyo Tuesday, April 2 ...

Ahmedabad: Zydus Lifesciences Limited has received approval from the Drugs Controller General of India (DCGI) to initiate ...